18F-Fluoromisonidazole in tumor hypoxia imaging - PubMed (original) (raw)

Review

18F-Fluoromisonidazole in tumor hypoxia imaging

Zuoyu Xu et al. Oncotarget. 2017.

Abstract

Hypoxia is a common feature of solid tumors that is closely associated with radiotherapy and chemotherapy resistance, metastasis and tumors prognosis. Thus, it is important to assess hypoxia in tumors for estimating prognosis and selecting appropriate treatment procedures. 18F-Fluoromisonidazole positron emission tomography (18F-FMISO PET) has been widely used to visualize tumor hypoxia in a comprehensive and noninvasive way, both in the clinical and preclinical settings. Here we review the concept, mechanisms and detection methods of tumor hypoxia. Furthermore, we discuss the correlation between 18F-FMISO PET and other detection methods, current applications of 18F-FMISO PET and the development prospects of this imaging technology.

Keywords: 18F-Fluoromisonidazole; PET; hypoxia; tumor.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

Figures

Figure 1. Chemical structure of 18F-FMISO

Figure 2. PET imaging

Major organs and regions uptake at 2 h after injection of 18F-FMISO (B) in small cell lung cancer patient. Arrows point to tumor. (Wei Y, Zhao W, Huang Y, Yu Q, Zhu S, et al. (2016). A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. PLOS ONE 11(6): e0157606.

https://doi.org/10.1371/journal.pone.0157606

).

Similar articles

• High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
  Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, Kuge Y, Shirato H, Tamaki N. Okamoto S, et al. J Nucl Med. 2013 Feb;54(2):201-7. doi: 10.2967/jnumed.112.109330. Epub 2013 Jan 15. J Nucl Med. 2013. PMID: 23321456
• The Roles of Hypoxia Imaging Using 18F-Fluoromisonidazole Positron Emission Tomography in Glioma Treatment.
  Hirata K, Yamaguchi S, Shiga T, Kuge Y, Tamaki N. Hirata K, et al. J Clin Med. 2019 Jul 24;8(8):1088. doi: 10.3390/jcm8081088. J Clin Med. 2019. PMID: 31344848 Free PMC article. Review.
• Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
  Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Bruehlmeier M, et al. J Nucl Med. 2004 Nov;45(11):1851-9. J Nucl Med. 2004. PMID: 15534054 Clinical Trial.
• 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
  Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, Yamazaki H, Naito Y, Senda M. Kikuchi M, et al. Ann Nucl Med. 2011 Nov;25(9):625-33. doi: 10.1007/s12149-011-0508-9. Epub 2011 Jul 1. Ann Nucl Med. 2011. PMID: 21720778
• [18F]-3-Fluoro-2-(4-((2-nitro-1_H_-imidazol-1-yl)methyl)-1_H_-1,2,3-triazol-1-yl)propan-1-ol.
  Chopra A. Chopra A. 2010 Aug 16 [updated 2010 Sep 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2010 Aug 16 [updated 2010 Sep 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20945565 Free Books & Documents. Review.

Cited by

• The Promise of Novel Biomarkers for Head and Neck Cancer from an Imaging Perspective.
  Marcu LG, Reid P, Bezak E. Marcu LG, et al. Int J Mol Sci. 2018 Aug 24;19(9):2511. doi: 10.3390/ijms19092511. Int J Mol Sci. 2018. PMID: 30149561 Free PMC article. Review.
• 2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.
  Maier FC, Schweifer A, Damaraju VL, Cass CE, Bowden GD, Ehrlichmann W, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G. Maier FC, et al. Pharmaceuticals (Basel). 2019 Feb 15;12(1):31. doi: 10.3390/ph12010031. Pharmaceuticals (Basel). 2019. PMID: 30781409 Free PMC article.
• Biological validation of electron paramagnetic resonance (EPR) image oxygen thresholds in tissue.
  Gertsenshteyn I, Giurcanu M, Vaupel P, Halpern H. Gertsenshteyn I, et al. J Physiol. 2021 Mar;599(6):1759-1767. doi: 10.1113/JP278816. Epub 2020 Jun 28. J Physiol. 2021. PMID: 32506448 Free PMC article. Review.
• Insights into Hypoxia: Non-invasive Assessment through Imaging Modalities and Its Application in Breast Cancer.
  Daimiel I. Daimiel I. J Breast Cancer. 2019 Jun;22(2):155-171. doi: 10.4048/jbc.2019.22.e26. J Breast Cancer. 2019. PMID: 31281720 Free PMC article. Review.
• Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
  McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S, Muschel RJ, Ng SM, Panakis N, Prevo R, Strauss VY, Stuart R, Tacconi EMC, Vallis KA, McKenna WG, Macpherson RE, Higgins GS. McGowan DR, et al. Eur J Cancer. 2019 May;113:87-95. doi: 10.1016/j.ejca.2019.03.015. Epub 2019 Apr 13. Eur J Cancer. 2019. PMID: 30991262 Free PMC article. Clinical Trial.

References

1. 1. Guillaumond F, Leca J, Olivares O, Lavaut MN, Vidal N, Berthezene P, Dusetti NJ, Loncle C, Calvo E, Turrini O, Iovanna JL, Tomasini R, Vasseur S. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110:3919–24. https://doi.org/10.1073/pnas.1219555110. - DOI - PMC - PubMed
2. 1. Ren Y, Hao P, Dutta B, Cheow ES, Sim KH, Gan CS, Lim SK, Sze SK. Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies. Mol Cell Proteomics. 2013;12:485–98. https://doi.org/10.1074/mcp.M112.018325. - DOI - PMC - PubMed
3. 1. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev. 2007;26:223–4. https://doi.org/10.1007/s10555-007-9058-y. - DOI - PubMed
4. 1. Cardenas-Navia LI, Richardson RA, Dewhirst MW. Targeting the molecular effects of a hypoxic tumor microenvironment. Front Biosci. 2007;12:4061–78. - PubMed
5. 1. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69:4–10. https://doi.org/10.1159/000088478. - DOI - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Impact Journals, LLC
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations